OTC label reform focus on areas of agreement with industry urged by NDMA's Soller.
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC LABEL REFORM: POTENTIAL AREAS OF AGREEMENT WITH INDUSTRY INCLUDE order of information, interchangeable terms and bulleted listings, Nonprescription Drug Manufacturers Association Senior VP-Science and Technology William Soller, PhD, said at a Jan. 18 Drug Information Association workshop on OTC drug labeling and consumer communication. Soller suggested that FDA and industry "might center" their initial efforts in reforming OTC drug labeling on these three areas.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning